Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naive Type 2 Diabetes following Equivalent Weight Loss

被引:22
|
作者
Straznicky, Nora E. [1 ]
Grima, Mariee T. [1 ]
Sari, Carolina I. [1 ]
Lambert, Elisabeth A. [1 ,2 ,3 ]
Phillips, Sarah E. [1 ]
Eikelis, Nina [1 ]
Mariani, Justin A. [4 ,5 ]
Kobayashi, Daisuke [1 ]
Hering, Dagmara [1 ]
Dixon, John B. [1 ,6 ]
Lambert, Gavin W. [1 ,5 ]
机构
[1] Baker IDI Heart & Diabet Inst, Human Neurotransmitters Lab, Melbourne, Vic, Australia
[2] Monash Univ, Dept Physiol, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Physiol, Melbourne, Vic, Australia
[4] Baker IDI Heart & Diabet Inst, Heart Failure Res Grp, Melbourne, Vic, Australia
[5] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[6] Monash Univ, Dept Primary Hlth Care, Melbourne, Vic, Australia
来源
FRONTIERS IN PHYSIOLOGY | 2016年 / 7卷
基金
澳大利亚国家健康与医学研究理事会;
关键词
sympathetic nervous system; obesity; weight loss; hypocaloric diet; glucose tolerance; hyperinsulinemia; type; 2; diabetes; ARTERIAL BAROREFLEX CONTROL; BETA-CELL FUNCTION; NEURAL ACTIVATION; PLASMA NOREPINEPHRINE; RISK-FACTORS; HEART-RATE; INSULIN; LEPTIN; GAIN; HYPERTENSION;
D O I
10.3389/fphys.2016.00516
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background and Purpose: Elevated sympathetic nervous system (SNS) activity is a characteristic of obesity and type 2 diabetes (T2D) that contributes to target organ damage and cardiovascular risk. In this study we examined whether baseline metabolic status influences the degree of sympathoinhibition attained following equivalent dietary weight loss. Methods: Un-medicated obese individuals categorized as normal glucose tolerant (NGT, n = 15), impaired glucose tolerant (IGT, n = 24), and newly-diagnosed T2D (n = 15) consumed a hypocaloric diet (29% fat, 23% protein, 45% carbohydrate) for 4-months. The three groups were matched for baseline age (56 +/- 1 years), body mass index (BMI, 32.9 +/- 0.7 kg/m(2)), and gender. Clinical measurements included whole-body norepinephrine kinetics, muscle sympathetic nerve activity (MSNA, by microneurography), spontaneous cardiac baroreflex sensitivity (BRS), and oral glucose tolerance test. Results: Weight loss averaged -7.5 +/- 0.8, -8.1 +/- 0.5, and -8.0 +/- 0.9% of body weight in NGT, IGT, and T2D groups, respectively. T2D subjects had significantly greater reductions in fasting glucose, 2-h glucose and glucose area under the curve (AUC(0-120)) compared to NGT and IGT (group effect, P < 0.001). Insulinogenic index decreased in IGT and NGT groups and increased in T2D (group x time, P = 0.04). The magnitude of reduction in MSNA (-7 +/- 3, -8 +/- 4, -15 +/- 4 burst/100 hb, respectively) and whole-body norepinephrine spillover rate (-28 +/- 8, -18 +/- 6, and -25 +/- 7%, respectively), time effect both P < 0.001, did not differ between groups. After adjustment for age and change in body weight, Delta insulin AUC(0-120) was independently associated with reduction in arterial norepinephrine concentration, whilst Delta LDL-cholesterol and improvement in BRS were independently associated with decrease in MSNA. Conclusions: Equivalent weight loss through hypocaloric diet is accompanied by similar sympathoinhibition in matched obese subjects with different baseline glucose tolerance. Attenuation of hyperinsulinemia and hyperlipidemia, rather than glycemic indices, is associated with reduction in SNS activity following weight loss intervention.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes
    Rohde, Ulrich
    Federspiel, Cecilie A.
    Vilmann, Peter
    Langholz, Ebbe
    Friis, Steffen U.
    Krakauer, Martin
    Rehfeld, Jens F.
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETES OBESITY & METABOLISM, 2017, 19 (02) : 189 - 199
  • [2] In Vivo Insulin Sensitivity and Secretion in Obese Youth What are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes?
    Bacha, Fida
    Gungor, Neslihan
    Lee, SoJung
    Arslanian, Silva A.
    DIABETES CARE, 2009, 32 (01) : 100 - 105
  • [3] Assessment of Insulin Resistance in Subjects with Normal Glucose Tolerance, Hyperinsulinemia with Normal Blood Glucose Tolerance, Impaired Glucose Tolerance, and Newly Diagnosed Type 2 Diabetes (Prediabetes Insulin Resistance Research)
    Yang, Guang
    Li, Chunlin
    Gong, Yanping
    Fang, Fusheng
    Tian, Hui
    Li, Jian
    Cheng, Xiaoling
    JOURNAL OF DIABETES RESEARCH, 2016, 2016
  • [4] The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes
    Oh, Tae Jung
    Kim, Min Young
    Shin, Ji Yon
    Lee, Jung Chan
    Kim, Sungwan
    Park, Kyong Soo
    Cho, Young Min
    CLINICAL ENDOCRINOLOGY, 2014, 80 (02) : 221 - 227
  • [5] Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: The role of immune cell activation and insulin resistance
    Samaras, Katherine
    Viardot, Alexander
    Lee, Ping N.
    Jenkins, Alicia
    Botelho, Natalia K.
    Bakopanos, Anthea
    Lord, Reginald V.
    Hayward, Christopher S.
    DIABETES & VASCULAR DISEASE RESEARCH, 2013, 10 (01) : 40 - 48
  • [6] Plasma adiponectin levels in high risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes
    Osei, K
    Gaillard, T
    Schuster, D
    OBESITY RESEARCH, 2005, 13 (01): : 179 - 185
  • [7] Effects of agar (kanten) diet on obese patients with impaired glucose tolerance and type 2 diabetes
    Maeda, H
    Yamamoto, R
    Hirao, K
    Tochikubo, O
    DIABETES OBESITY & METABOLISM, 2005, 7 (01) : 40 - 46
  • [8] Rise in fasting and dynamic glucagon levels in children and adolescents with obesity is moderate in subjects with impaired fasting glucose but accentuated in subjects with impaired glucose tolerance or type 2 diabetes
    Pixner, Thomas
    Chaikouskaya, Tatsiana
    Lauth, Wanda
    Zimmermann, Georg
    Moerwald, Katharina
    Lischka, Julia
    Furthner, Dieter
    Awender, Elisabeth
    Geiersberger, Sabine
    Maruszczak, Katharina
    Forslund, Anders
    Anderwald, Christian-Heinz
    Cadamuro, Janne
    Weghuber, Daniel
    Bergsten, Peter
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [9] Digestive, Anorectal, and Urogenital Functions in Patients with Type 2 Diabetes Mellitus, Impaired Glucose Tolerance and Normal Glucose Tolerance: Association with Autonomic Neuropathy
    Quast, Daniel R.
    Boronikolos, Georgios C.
    Menge, Bjoern A.
    Breuer, Thomas G. K.
    Schenker, Nina
    Meier, Juris J.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (05) : 299 - 306
  • [10] Antihypertensive drugs as predictors of Type 2 diabetes among subjects with impaired glucose tolerance
    Rajala, U
    Qiao, Q
    Laakso, M
    Keinänen-Kiukaanniemi, S
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2000, 50 (03) : 231 - 239